

Octreotide – What is your experience?

February – March 2010

Number of responses = 76

1) For which of the following indications have you used octreotide? (many_of)

answer	votes	% of voters
Symptoms associated with unresectable hormone-secreting tumours e.g. carcinoid, VIPomas, glucagonomas	54	71
Acromegaly	1	1
Prevention of complications following pancreatic surgery	2	3
Bleeding oesophageal varices	16	21
Salivary, pancreatic or enterocutaneous fistulas	36	47
Buccal fistula	3	4
Intractable diarrhoea related to high output ileostomies	56	74
Inoperable bowel obstruction in patients with cancer	73	96
Hypertrophic pulmonary osteo-arthritis	1	1
Ascites in cirrhosis	1	1
Ascites in cancer	13	17
Death rattle	6	8
Bronchorrhoea	9	12
Reduction of tumour related secretions	26	34
Intractable diarrhoea associated with AIDS	10	13
Intractable diarrhoea associated with bone marrow transplant	2	3
Intractable diarrhoea associated with chemotherapy	10	13
Intractable diarrhoea associated with radiation therapy	13	17

2) What is your usual *starting* dose/24h for octreotide in the treatment of inoperable bowel obstruction in patients with cancer? Freetext

answer	votes	% of vote
100microgram/24h	4	5
150microgram/24h	3	4
200microgram/24h	7	10
250microgram/24h	4	5
300microgram/24h	30	41
400microgram/24h	7	10
500microgram/24h	10	14
600microgram/24h	6	8
Other (reported as 900microgram and 1,000microgram/24h)	2	3

3) What is your usual *maximum* dose/24h for octreotide in the treatment of inoperable bowel obstruction in patients with cancer? Freetext

answer	votes	% of vote
300microgram/24h	2	3
400microgram/24h	1	1
500microgram/24h	3	4
600microgram/24h	9	13
800microgram/24h	8	11
900microgram/24h	8	11
1,000microgram/24h	20	28
1,200microgram/24h	10	14
1,500microgram/24h	3	4
2,000microgram/24h	3	4
Other (reported as 2.4mg, 3mg, 3.6mg and 6mg/24h)	4	6

4) How do you generally administer octreotide in the treatment of inoperable bowel obstruction in patients with cancer? (one_of)

<i>answer</i>	<i>votes</i>	<i>% of vote</i>
SC bolus injection(s)	13	17%
CSCI	59	78%
Other (please specify in the comments section below)	1	1%
Do not use octreotide for this indication	1	1%

5) If you administer octreotide *alone* as a CSCI, what diluent do you use? (one_of)

<i>answer</i>	<i>votes</i>	<i>% of vote</i>
Water for injection	20	26%
Water for injection but would consider 0.9% saline for large doses	2	3%
0.9% saline	40	53%
Other (please specify in the comments section below)	0	0%
Do not use CSCI	7	9%

6) What diluent do you generally use when mixing octreotide with other drugs for CSCI? (one_of)

<i>answer</i>	<i>votes</i>	<i>% of vote</i>
Water for injection	20	26%
Water for injection, but 0.9% saline with other irritant drugs	3	4%
0.9% saline	23	30%
0.9% saline, but water for injection if there is no compatibility data	4	5%
Other (please specify in the comments section below)	0	0%
Do not mix octreotide with other drugs	20	26%

7) Which of the following drugs have you successfully mixed together with octreotide in *water for injection*? (many_of)

<i>answer</i>	<i>votes</i>	<i>% of voters</i>
Clonazepam	2	3
Cyclizine	7	9
Dexamethasone	1	1
Glycopyrronium	3	4
Granisetron	0	0
Haloperidol	11	14
Hydromorphone	1	1
Hyoscine hydrobromide	4	5
Ketamine	0	0
Ketorolac	0	0
Levomepromazine	13	17
Midazolam	14	18
Morphine Tartrate	2	3
Do not mix octreotide with drugs in water for injection	29	38

8) Which of the following drugs have you successfully mixed with octreotide in 0.9% saline? (many_of)

<i>answer</i>	<i>votes</i>	<i>% of voters</i>
Alfentanil	2	3
Clonazepam	3	4
Dexamethasone	2	3
Glycopyrronium	2	3
Granisetron	1	1
Hydromorphone	3	4
Ketamine	1	1
Ketorolac	1	1
Levomepromazine	11	14
Metoclopramide	8	11
Do not mix octreotide with drugs in 0.9% saline	32	42

9) Do you ever use a depot formulation for the treatment of inoperable bowel obstruction in patients with cancer? (one_of)

<i>answer</i>	<i>votes</i>	<i>% of vote</i>
Yes, octreotide depot (Sandostatin LAR)	13	17%
Yes, lanreotide depot (Somatuline LA)	10	13%
Yes, lanreotide depot (Somatuline Autogel)	3	4%
No	45	59%

10) Further comments

Only a few comments were received, the majority were related to the use of a depot formulation with members reporting that they have used this formulation to enable patients to go home.